A multicenter observational study using multigene assays to assess the risk of early recurrence in hormone receptor-positive, HER2-negative early breast cancer(WJOG16722B)

A multicenter observational study using multigene assays (MammaPrint/BluePrint) to assess the risk of early recurrence in hormone receptor-positive, HER2-negative early breast cancer(WJOG16722B) - RealisE-TR

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050930

Enrollment

120

Registered

2023-04-26

Start date

2023-10-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hormone receptor positive and HER2 negative early breast cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Patients enrolled in the WJOG15721B study 2) Patients with a submittable surgical specimen or needle biopsy specimen at the time of breast cancer diagnosis 3) Cases selected in accordance with the "Selection of Cases" section of the protocol for this study 4) Cases with informed consent to participate in this study

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Proportion of high risk by MammaPrint	—

Secondary

Measure	Time frame
1)Proportion of basal type by BluePrint 2)Molecular subtype by BluePrint, relationship between MammaPrint/BluePrint and clinicopathological factors	—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results